Skip to main content

COVID-19

      My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.
      RT @ELittlejohnDO: Love this COVID ARDS risk calculator put forth by @JYazdanyMD at #ACR21 for our patient's with Rheuma

      Emily Littlejohn ELittlejohnDO

      3 years 6 months ago
      Love this COVID ARDS risk calculator put forth by @JYazdanyMD at #ACR21 for our patient's with Rheumatic Diseases. A wonderful resource in talking to our patients about vaccine necessity! @CleClinicMD https://t.co/EA5jVYweHm
      RT @Doctorkuch: #ACR21 Late breaking
      #ACRambassador
      Breakthrough COVID-19 Infections Post-vaccination Among Immunocompr

      Marie Kuchynski MD Doctorkuch

      3 years 6 months ago
      #ACR21 Late breaking #ACRambassador Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled EMR Data Repository https://t.co/oyovR27Upm
      RT @swethaann23: Reasons for COVID-19 vaccine hesitancy in rheumatology pts in southeast US based on survey study:

      🔰

      swethaann23 swethaann23

      3 years 6 months ago
      Reasons for COVID-19 vaccine hesitancy in rheumatology pts in southeast US based on survey study: 🔰Vaccine being “rushed” or “experimental” 🔰Safety of vaccine in the patients’ rheumatologic diagnoses 🔰Side effects 🔰Concern for Allergic reaction Abst#1589 #ACR21 @RheumNow https://t.co/xm15KxdA56
      Factors Associated with Poor Vaccine Response in Rituximab: Dr. Yuzaiful Yusof (@Yuz6Yusof) discusses abstract #0437 pre

      Dr. John Cush RheumNow

      3 years 6 months ago
      Factors Associated with Poor Vaccine Response in Rituximab: Dr. Yuzaiful Yusof (@Yuz6Yusof) discusses abstract #0437 presented at the #ACR21 annual meeting. https://t.co/T0PFiZlbTa https://t.co/idj5T7j7ke
      Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE from Dr. Yuz Yusof ( @Yuz6Yusof)
      It's almost a year since

      Dr. John Cush RheumNow

      3 years 6 months ago
      Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE from Dr. Yuz Yusof ( @Yuz6Yusof) It's almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under EUA. But is the vaccine safe for people with lupus? https://t.co/i3HeCvS6El https://t.co/Tn0nWKrK4T
      Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.
      RT @RichardPAConway: GRA @rheum_covid data presented by @mugartegil. African-American and Hispanic individuals with SLE

      Richard Conway RichardPAConway

      3 years 6 months ago
      GRA @rheum_covid data presented by @mugartegil. African-American and Hispanic individuals with SLE have MUCH worse COVID-19 outcomes. Likely related socioeconomic and health disparities. Abstr#1933 #ACR21 @RheumNow https://t.co/YUoOeIxN7O
      RT @AurelieRheumo: 🚫Infection risk after COVID vaccination: US database
      536 954 Controls and 47 303 pts w/ RMDs
      〽ï

      Aurelie Najm AurelieRheumo

      3 years 6 months ago
      🚫Infection risk after COVID vaccination: US database 536 954 Controls and 47 303 pts w/ RMDs 〽️BNT162b2 19 vs. 36/1000 〽️ mRNA-1273 16 vs. 33/1000 〽️Janssen 26 vs. 47/1000 Infections ⬆️ RA, SpA, SLE, SSc, Polymyositis #ACR21 #AbstL16 @RheumNow https://t.co/xzOaFIu06e @RheumNow https://t.co/tmr4USETJ3
      RT @Yuz6Yusof: #ACR21 #AbstrL17 In pts treated with Rituximab, arrange a 3rd primary dose ASAP regardless mRNA or vector

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 6 months ago
      #ACR21 #AbstrL17 In pts treated with Rituximab, arrange a 3rd primary dose ASAP regardless mRNA or vector #COVID vaccine. An RCT of N=60 pts who did not seroconvert after primary dose, overall 94% either seroconverted/new T-cell response @RheumNow #ACRBest https://t.co/F15j93OFE4 https://t.co/tXoisoYthx
      RT @AkhilSoodMD: CH COVID 19 Poster Review
      Abst 0196
      Jackson & colleagues performed double blind RCT of anakinra in

      Akhil Sood MD AkhilSoodMD

      3 years 6 months ago
      CH COVID 19 Poster Review Abst 0196 Jackson & colleagues performed double blind RCT of anakinra in patients with features of COVID-19 cytokine storm - Anakinra + GC did not significantly impact outcomes in patients with cytokine storm syndrome #ACR21 @RheumNow https://t.co/hX7bBtrIzT
      RT @uptoTate: Late breaking, but just in time! mRNA COVID-19 3rd dose in RTX pts, w/o Ab response post initial series.

      Dr. Rachel Tate uptoTate

      3 years 6 months ago
      Late breaking, but just in time! mRNA COVID-19 3rd dose in RTX pts, w/o Ab response post initial series. After 3rd dose many had ab response or T cell response. Extra vaccine full doses can protect RTX pts from COVID! AbsL17 #ACRbest #ACR21 @RheumNow https://t.co/lIDPzybmT7 https://t.co/jEJ3N6cdjK
      Complications of Covid19 in Lupus: Dr. Kathryn Dao ( @KDAO2011) discusses abstract #1933 presented at the #ACR21 annual

      Dr. John Cush RheumNow

      3 years 6 months ago
      Complications of Covid19 in Lupus: Dr. Kathryn Dao ( @KDAO2011) discusses abstract #1933 presented at the #ACR21 annual meeting. https://t.co/jKFJwCBeCo https://t.co/ncleyYZWLn
      ×